0001209191-22-033210.txt : 20220601 0001209191-22-033210.hdr.sgml : 20220601 20220601170702 ACCESSION NUMBER: 0001209191-22-033210 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220519 FILED AS OF DATE: 20220601 DATE AS OF CHANGE: 20220601 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Levin Andrew David CENTRAL INDEX KEY: 0001867539 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40708 FILM NUMBER: 22988214 MAIL ADDRESS: STREET 1: C/O ELIEM THERAPEUTICS, INC. STREET 2: 23515 NE NOVELTY HILL RD, STE B221 #125 CITY: REDMOND STATE: WA ZIP: 98053 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eliem Therapeutics, Inc. CENTRAL INDEX KEY: 0001768446 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832273741 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 23515 NE NOVELTY HILL ROAD STREET 2: SUITE B221 #125 CITY: REDMOND STATE: WA ZIP: 98053 BUSINESS PHONE: 425-276-2300 MAIL ADDRESS: STREET 1: 23515 NE NOVELTY HILL ROAD STREET 2: SUITE B221 #125 CITY: REDMOND STATE: WA ZIP: 98053 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-19 0 0001768446 Eliem Therapeutics, Inc. ELYM 0001867539 Levin Andrew David C/O ELIEM THERAPEUTICS, INC. 23515 NE NOVELTY HILL RD, STE. B221 #125 REDMOND WA 98053 1 0 0 0 Stock Option (Right to Buy) 3.46 2022-05-19 4 A 0 10000 0.00 A 2032-05-18 Common Stock 10000 10000 D The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock. /s/ Brian Woodard, Attorney-in-Fact 2022-06-01